Study product Indication Comparator Treatment duration (weeks) Results vs comparator MF 0.1 % Cream QD Atopic Dermatitis Vehicle QD 3 Significantly superior [30] Hydrocortisone butyrate 0.05 % BID 3 Significantly superior [32] Betamethasone valerate 0.1 % BID 3 Comparable [35] AD pediatrics* Hydrocortisone valerate 0.2 % BID 3 Significantly superior [33] AD pediatrics Hydrocortisone 1.0 % BID 6 Significantly superior [34] Psoriasis Vehicle QD 3 Significantly superior [42] Psoriasis Betamethasone valerate 0.1 % BID 2 Comparable [44] Corticosteroid-responsive dermatoses Betamethasone dipropionate 0.05 % BID   No significant differences [66] Chronic eczema Clobetasol propionate 0.05 % BID 3 Inferior patient satisfaction [67] MF 0.1 % Ointment QD Atopic Dermatitis Vehicle QD 3 More effective [31] Betamethasone valerate 0.1 % BID 3 Comparable [36] Hydrocortisone Butyrate 0.1 % BID 3 comparable [37] AD pediatrics** Fluticasone propionate 0.005 % QD 4 Comparable [38] Psoriasis Vehicle QD 3 Significantly superior [43] Triamcinolone acetonide BID 3 Significantly superior [47] Fluocinolone Acetonide TID 3 Significantly superior [48] Betamethasone dipropionate 0.05 % QD 3 Comparable [45] Betamethasone valerate 0.1 % BID 3 Significantly superior [49] Hydrocortisone QD 6 Significantly superior [50] MF 0.1 % Cream and Ointment QD Psoriasis Fluocinolone acetonide 0.025 % Cream and Ointment TID 3 Significantly superior (both cream and ointment) [46] Triamcinolone acetonide 0.1 % Cream and Ointment BID 3 Significantly superior (ointment) and comparable (cream) [46] MF 0.1 % Solution QD Scalp psoriasis Vehicle QD   Significantly superior [53] Betamethasone valerate 0.1 % BID   Slightly superior [54] Betamethasone dipropionate 0.05 % QD   Slightly superior [55] Triamcinolone acetonide 0.1 % BID 7 Significantly superior [56] *Patients who failed to previous topical hydrocortisone **Comparing Open and Wet wrap dressing (better long-term improvement when using wet wrap dressing) MF: Mometasone furoate. AD: Atopic dermatitis. QD: Once daily; BID: twice a day; TID: three times per day

Table 1: Study profile of the current mometasone furoate formulations in different skin diseases.